Search clinical trials for: anlotinib, fulvestrant

Total 1864 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib in Patients With Hepatocellular Carcinoma (ALTER0802)

Hepatocellular Carcinoma

China
Peking University Third Hospital

Not yet recruiting

A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma

Ovarian Clear Cell Carcinoma
Henan Provincial People's Hospital

Not yet recruiting

Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC (SAINT)

Non Small Cell Lung Cancer

China
Chinese PLA General Hospital

Not yet recruiting

A Study of Combination Therapy in NSCLC

Non-small Cell Lung Cancer
Zhejiang University
Huashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Terminated

A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

Hepatocellular Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Phase II Study of Anlotinib in MTC Patients (ALTN/MTC)

Tumor

China
Ningbo No.2 Hospital

Not yet recruiting

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY)

Carcinoma, Non-Small-Cell Lung
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
Henan Cancer Hospital

Completed

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Extensive Disease Small Cell Lung Cancer

China
Yansong Lin

Active, not recruiting

Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib

DTC - Differentiated Thyroid Cancer

China
Yizhuo Zhang

Unknown

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Differentiated Thyroid Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

Small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...
Zhejiang Cancer Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing... and other collaborators

Unknown

Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy

Soft Tissue Sarcoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

Soft Tissue Sarcoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nanjing Medical University

Completed

A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics (ALTN)

Advanced Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Small Cell Lung Carcinoma

China
Zhongda Hospital

Recruiting

TACE Combined With Penpulimab and Anlotinib for Advanced HCC

Hepatocellular Carcinoma

China
Qianfoshan Hospital

Recruiting

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Advanced Non-small Cell Lung Cancer

China
Shanghai Gopherwood Biotech Co., Ltd.

Not yet recruiting

BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer (CAN-RESPOND)

Endometrial Cancer
Henan Cancer Hospital

Recruiting

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor

Desmoid

China
Shanghai Chest Hospital
3D Medicines

Not yet recruiting

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma

Anlotinib | Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound Complications

China
Peking University

Recruiting

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Gastric Cancer | Colo-rectal Cancer

China
Anhui Shi, MD
Peking University Cancer Hospital & Institute; Chia Tai Tianqing Pharmaceutical...

Completed

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） (ALTER-L029)

Non-Small Cell Lung Cancer Stage III

China
Taizhou Hospital

Completed

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Small Cell Lung Cancer Recurrent

China
Akeso

Active, not recruiting

A Trial of AK104 Plus Anlotinib in NSCLC

NSCLC

China
The First Hospital of Jilin University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC

Non-Small Cell Lung Cancer

China
First Affiliated Hospital Xi'an Jiaotong University
Tang-Du Hospital; Yan'an University Affiliated Hospital

Unknown

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

Non-squamous NSCLC

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

Esophageal Squamous Cell Carcinoma

China
LanZhou University
General Hospital of Ningxia Medical University

Unknown

Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

Advanced Non-squamous NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

Gastric Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Stage III Non-small-cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Non Clear Cell Renal Carcinoma

China
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
Zhejiang University

Recruiting

TAS-102 and Anlotinib in ≥3 Lines mGC

Gastric Cancer

China
Sun Yat-sen University

Active, not recruiting

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Nasopharyngeal Carcinoma | Recurrent or Metastatic Nasopharyngeal Carcinoma

China
Hunan Cancer Hospital

Completed

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Metastatic Breast Cancer

China
Shanghai Minimally Invasive Surgery Center

Withdrawn

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Rectal Cancer | Anlotinib | Neoadjuvant Treatment
Shanghai Zhongshan Hospital

Withdrawn

Adjuvant Therapy With Anlotinib for HCC

Hepatocellular Carcinoma

China
Shanghai Changzheng Hospital

Unknown

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE)

Gastric Cancer | Immunotherapy | Anlotinib | Toripalimab | Gastro-oesophageal Junction Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Xijing Hospital

Not yet recruiting

Adjuvant Treatment of Digestive Tract Tumors (ATDTT)

Adjuvant Treatment
University of Arkansas
OSI Pharmaceuticals

Terminated

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Metastatic Breast Cancer

United States
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

First-line Anlotinib Combined With Penpulimab for Advanced Pheochromocytoma: A Single-arm, Multicenter, Prospective Phase II Study

Pheochromocytoma

China
Fudan University

Recruiting

HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

Hepatocarcinoma

China
Lyvgen Biopharma Holdings Limited

Recruiting

A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma

Soft Tissue Sarcoma

China

Search clinical trials for: anlotinib, fulvestrant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations